Anti-Human ADAMTS4 Recombinant Antibody (7C7.1H1) (CAT#: TAB-0676CLV)

Figure 1 Potent and sustained inhibition of aggrecanolysis from human OA cartilage explants by ADAMTS-5 mAb treatment.

ADAMTS-5 mAb treatment inhibits ARGS neoepitope release from sequentially unstimulated and IL-1b/OSM stimulated human OA cartilage explants, whereas only modest inhibition is observed with ADAMTS-4 mAb treatment, preferentially under cytokine-stimulated conditions. Mean percent inhibition of mAbs is shown relative to isotype control mAb (0% inhibition, dashed lines in a and b) and GSK571949 (100% inhibition) treatment. Experiments were conducted with seven replicates for each treatment condition from eight timepoints across multiple 28-day experiments consisting of a 21 day unstimulated phase followed by a 7-day cytokine-stimulated phase. A total of 13–28 independent OA patient experiments were conducted for each treatment condition. ADAMTS-4 (7E8.1E3 or 7C71.H1) and ADAMTS-5 (12F4.1H7 or 7B4.1E11) mAb treatments are shown as compiled data associated with each mAb specificity.

Larkin, J., Lohr, T. A., Elefante, L., Shearin, J., Matico, R., Su, J. L., ... & Tran, P. B. (2015). Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis and cartilage, 23(8), 1254-1266.

Figure 2 ADAMTS-4 and ADAMTS-5 mAbs specifically bind to and potently inhibit aggrecanase activity.

Functional potency of ADAMTS-4 mAbs and non-selective small molecule (GSK579149) is quantified vs isotype controls (not shown) by measuring percent inhibition of selective aggrecanase-mediated ARGS neoepitope formation from purified bovine aggrecan substrate.

Larkin, J., Lohr, T. A., Elefante, L., Shearin, J., Matico, R., Su, J. L., ... & Tran, P. B. (2015). Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis and cartilage, 23(8), 1254-1266.